- Home
- VNET vs DNLI Comparison
VNET vs DNLI Comparison
Compare VNET & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNET | DNLI |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VNET | DNLI |
|---|---|---|
| Price | $8.91 | $17.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $16.30 | ★ $32.58 |
| AVG Volume (30 Days) | ★ 3.7M | 1.7M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,335,622,122.00 | N/A |
| Revenue This Year | $21.36 | N/A |
| Revenue Next Year | $18.93 | $3,993.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $3.52 | $10.57 |
| 52 Week High | $16.13 | $24.35 |
Technical Indicators
Market Signals| Indicator | VNET | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 46.56 |
| Support Level | $8.46 | $17.20 |
| Resistance Level | $9.36 | $18.30 |
| Average True Range (ATR) | 0.37 | 1.03 |
| MACD | 0.05 | -0.27 |
| Stochastic Oscillator | 39.19 | 5.71 |
Price Performance
Historical ComparisonAbout VNET VNET Group Inc.
VNET started as AsiaCloud in 1999 and moved into the data center business, opening its first self-developed data center in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of September 2025, it had 52,288 retail cabinets, with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 783 MW of wholesale capacity in service, with a further 306 MW under construction and a further 705 MW held for future development.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.